CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1 enrolled
Drug / intervention
No drug +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01604122
NCT01604122N/ACompleted

Cross-sectional, Non-interventional Burden Of Disease (Bod) Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (Ttr-fap) Or Transthyretin Cardiomyopathy (ttr-cm) And Caregivers

Pfizer·observational·Posted May 23, 2012·Updated Apr 6, 2023

In Brief

An observational study evaluating No drug for Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) and 3 related conditions. Completed, enrolled 1 participant.

Detailed Summary

This study is an online (web-based) or paper-based survey for patients with transthyretin familial amyloidosis polyneuropathy (TTR-FAP) and caregivers. The results will be used to describe the emotional, physical, and financial impact of having TTR-FAP or caring for someone who has the disease.

Study Details

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 23, 2012
Enrollment StartApr 18, 2012
Primary CompletionJul 27, 2015
Study CompletionJul 18, 2016
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 14.1 years ago

Interventions

No drugother

No drug.

No drugother

No drug.